Clinical Report: Natural Remedies for Modulating Macrophage Polarization in IPF

Overview

This narrative review explores the potential of natural product-based therapeutics in modulating macrophage polarization within the fibrotic environment of idiopathic pulmonary fibrosis (IPF). It highlights the limitations of current antifibrotic therapies.

Background

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease characterized by excessive extracellular matrix deposition and declining pulmonary function. Current FDA-approved antifibrotic agents, nintedanib and pirfenidone, show limited efficacy in reversing established fibrosis and are associated with significant adverse effects.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• Macrophages play a critical role in the progression of IPF through their regulation of the fibrotic niche.
• Conventional antifibrotics do not reverse existing fibrosis and have dose-limiting toxicities.
• Mechanisms such as immunometabolic shifts and mechanotransduction blockade are key to the therapeutic effects of phytochemicals.
• Future research should focus on empirical validation of these natural therapies using advanced methodologies.

Clinical Implications

Clinicians should consider the complexities of managing the immune interactions in IPF.

Conclusion

Natural product-based therapeutics may address the limitations of current IPF treatments by targeting macrophage polarization.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Microbiome-innate immune crosstalk in acute exacerbation of idiopathic pulmonary fibrosis: an amplification framework
2. Frontiers in Immunology, 2026 -- NAMPT orchestrates fibroblast cuproptosis and immune crosstalk during IPF progression
3. Frontiers in Immunology, 2026 -- Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages
4. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline - PMC
5. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis | New England Journal of Medicine
6. Frontiers in Immunology — Immunomodulatory effects of synthetic antimicrobial peptides on LPS-induced inflammatory responses in THP-1 macrophages
7. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline - PMC
8. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis | New England Journal of Medicine
9. Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial - PubMed